Test Price
4,600 AED✅ Home Collection Available
ONCOMINE Acute Myeloid Leukaemia (AML) Panel – Next‑Generation Sequencing
Executive Summary & Core Metrics
Clinical Excellence: 99.9% diagnostic sensitivity via ISO 9001:2015 accredited NGS processing.
Premium Logistics: Hospital Extraction Only – Sample collection is conducted strictly within an accredited hospital facility; mobile home phlebotomy is disabled for safety.
Post-Test Guidance: Complimentary telephonic clinical correlation with DHA-licensed Consultant Medical Geneticist.
Insurance Support: Direct billing verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The ONCOMINE AML Panel leverages Next‑Generation Sequencing (NGS) to interrogate 25+ clinically relevant genes—including NPM1, FLT3, IDH1/2, and CEBPA—providing a definitive molecular landscape for precise AML subtyping and targeted therapy selection.
| Feature | Our Test – ONCOMINE NGS Panel | Closest Alternative (Single‑Gene PCR) |
|---|---|---|
| Diagnostic Precision | 99.9% sensitivity; multigene simultaneous analysis | 85–90%; limited to one mutation at a time |
| Methodology | NGS (Next‑Generation Sequencing) – ISO 9001 accredited | PCR & Sanger sequencing |
| Turnaround Time | 15 working days (monthly batch processing) | 7–14 days per gene, cumulative delay |
| Therapeutic Impact | Identifies actionable targets (FLT3, IDH inhibitors) | Often requires sequential follow‑up testing |
Physician Insight & Safety Protocols
“As a DHA‑registered Consultant Medical Genetics, I emphasize that the ONCOMINE AML Panel reveals actionable genetic drivers; however, test results must always be correlated with bone marrow morphology, cytogenetics, and the patient’s full clinical picture. This test offers families a molecular blueprint of the leukaemia, opening the door to precisely tailored treatments – a hope I witness daily.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA License 9294403
Medication Advisory
Medication Warning:
Do not discontinue any prescribed anti‑leukaemic medication, anticoagulants, or supportive therapy without explicit instruction from your supervising consultant. Abrupt changes may trigger life‑threatening complications.
Exclusion Criteria & Emergency Red Flags
Exclusion Criteria: Sample must not be frozen; avoid heparin anticoagulants; a fully completed NGS Requisition Form (Form 40) is mandatory. If the patient has received a bone marrow transplant within the last 28 days, the laboratory must be informed.
ER Red Flags: If the patient experiences sudden high fever (>38.5°C), uncontrolled bleeding, or severe dyspnoea before the blood draw, postpone the collection and seek immediate emergency care.
Patient FAQ & Clinical Guidance
1. What does the ONCOMINE AML Panel actually test for?
This NGS panel precisely sequences over 25 acute myeloid leukaemia driver genes, delivering a comprehensive mutation profile that guides targeted therapy and risk stratification.
2. How is the sample collected and what are the precautions?
A DHA‑licensed phlebotomist performs a sterile venipuncture (3 mL blood in lavender‑top EDTA tube) or bone marrow aspirate, shipped refrigerated under strict cold‑chain exactly as required for NGS integrity. Collection occurs only at an accredited hospital facility.
3. When will I receive my results and who interprets them?
Results are available within 15 working days from batch closure; our oncology‑linked genetic consultants provide a detailed clinical interpretation and treatment correlation during the complimentary post‑test teleconsultation.
UAE Regulatory & Data Privacy Adherence
This diagnostic service operates under DHA Facility License Number 1143 and fully complies with Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All genetic data is securely encrypted, stored within UAE‑based servers, and accessible only to authorised healthcare professionals directly involved in your care. Your consent, as per Federal Decree‑Law No. 4 of 2016 on Medical Liability, is obtained before any sample collection or testing.
Clinical & Logistical Metadata
| Test Name | ONCOMINE Acute Myeloid Leukaemia (AML) Panel |
| Price (AED) | 4,600 AED |
| Turnaround Time | 15 working days (monthly batch processing) |
| Sample Type / Matrix | Hospital Extraction Only – Sample collection is conducted strictly within an accredited hospital facility; mobile home phlebotomy is disabled for safety. |
| Methodology Used | Next‑Generation Sequencing (NGS) |
| ICD-10-CM Code | C92.00 |
| LOINC Code | 88229-0 |
| DHA Facility License & Laboratory Address | License No. 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians